Liquidia Corporation reported $451M of revenue over the trailing twelve months, +2234% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $451M (to Q2 2026). Net Income: $139M, trailing twelve months to Q2 2026. Free Cash Flow: $151M, trailing twelve months to Q2 2026. Op Margin: 30%, trailing twelve months to Q2 2026.

LQDALiquidia Corporation

HealthcareUSD

$71.35

$20.4552 weeks$91.06

LQDA as reported

Liquidia Corporation reported $451M of revenue over the trailing twelve months, +2234% on the year before. 10 reported series are charted on this page, each one as filed.

$451M

Revenue, trailing twelve months · to Q2 2026 · +2234% against the twelve months before

Net Income: $139M
Net Income · −193% year on year · trailing twelve months to Q2 2026
Free Cash Flow: $151M
Free Cash Flow · −225% year on year · trailing twelve months to Q2 2026
Op Margin: 30%
Op Margin · trailing twelve months to Q2 2026

Every series Ryufin has for LQDA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$451M	+2234%	Q2 2026
Net Income	$139M	−193%	Q2 2026
EPS	$1.39	−178%	Q2 2026
Gross Margin	57%	n/a	Q1 2025 · 5 quarters behind
Op Margin	30%	n/a	Q2 2026
Net Margin	23%	n/a	Q2 2026
ROE	−154%	n/a	Q2 2026
ROA	−8.3%	n/a	Q2 2026
ROIC	−189%	n/a	Q4 2022 · 14 quarters behind
Free Cash Flow	$151M	−225%	Q2 2026